A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1
← catalyst calendarSponsored by Eisai Inc. (industry) · 4523.T — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
22actual
Sites
14
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-20 | actual | When the study began enrolling |
| Primary completion | 2025-03-17 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-03-17 | actual | The whole study's end, after follow-up |
| First posted | 2024-06-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Narcolepsy Type 1 (NT1)
Interventions
- Drug: E2086
- Drug: E2086 Placebo
- Drug: Active Comparator
- Drug: Active Comparator Placebo
Primary outcomes
what the primary-completion date above is the date OFMean Sleep Latency (MSL) as Assessed by the 4 Maintenance of Wakefulness Tests (MWTs) for E2086 Versus Placebo at Day 1
measured At Day 1
MSL as Assessed by the 4 MWTs for E2086 Versus Placebo at Day 5
measured At Day 5
MSL as Assessed by the 4 MWTs for E2086 Versus Placebo at Day 9
measured At Day 9
MSL as Assessed by the 4 MWTs for E2086 Versus Placebo at Day 13
measured At Day 13
MSL as Assessed by the 4 MWTs for E2086 Versus Placebo at Day 17
measured At Day 17
Permalink · 4523.T's whole pipeline · Catalyst calendar · Every registered study · What changed